Morphic Therapeutic is leading the development of a new generation of oral integrin drugs, informed by decades of world-leading expertise and a unique integrin discovery platform. Morphic believes oral drugs targeting the integrin protein family can transform the treatment paradigm for patients suffering from serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, as well as fibrosis and cancer.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Sep 26, 2023
Morphic to Present Positive EMERALD-1 Phase 2a Data for MORF-057 in Patients with Moderate to Severe Ulcerative Colitis in Abstract for UEGW 2023
Sep 22, 2023
Aug 29, 2023